21/08/2025 In a $350M deal, Kite to acquire Interius BioTherapeutics (Ref) Kite (a Gilead Company) entered into a definitive agreement to acquire Interius BioTherapeutics developing in vivo CAR therapeutics for $350 million. Interius’ off-the-shelf and personalized approach is designed to be delivered via a single IV infusion, eliminating the need for preconditioning chemotherapy and complex cell processing Under the terms of the agreement, Kite will acquire all of the outsta